علاج اللمفوما الجريبية المنتكسة المحتاجة إلى العلاج

References

Offer immunochemotherapy to people with relapsed FL in need of treatment.

For those who have achieved a relatively long remission duration, consider repeat therapy with rituximab in combination with the same chemotherapy as administered previously. For those with a shorter remission duration consider rituximab in combination with an alternative chemotherapy regimen from that administered previously.

Consider up to 2 years of rituximab (or obinutuzumab if this agent was used for induction) maintenance for those people who have relapsed disease who have responded to re-induction therapy, have not received antibody maintenance previously and are not suitable for high-dose therapy.

Consider HDT-ASCR for fitter people with relapsed FL who achieve a second or subsequent remission.